Regarding Neuromyelitis Optica Spectrum Disorder, the FDA has approved Ravulizumab-cwvz from Alexion.

Published Date: 28 Mar 2024

The approval is reinforced by phase 3 data, which demonstrated that ravulizumab-cwvz achieved its primary end point of not having any relapses in 58 patients with NMOSD over a median treatment duration of 73 weeks, with respect to the first on-trial relapse.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot